Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects (Q44270289)
scientific article
Language:
Current Data About Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects
(P31) (Q13442814)
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P304) 18-29
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P407) (Q1860)

(P433) 1
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P478) 32
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P577) Wednesday, January 1, 2003
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P921) (Q50430310)

(Q42824440)

(Q423467)
(P887)

(Q423984)
(P887)

(Q422606)
(P887)

(P1433) (Q6294722)
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P1476) "Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects" (language: en)
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

(P2093) Ian Sanne
(P1545) 1
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

Peter Piliero
(P1545) 2
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

Kathleen Squires
(P1545) 3
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

Alexandra Thiry
(P1545) 4
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

Steven Schnittman
(P1545) 5
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

AI424-007 Clinical Trial Group
(P1545) 6
(P248)
(P698) 12514410
(P813) Friday, December 1, 2017

other details
description scientific article

External Links
(P356) 10.1097/00126334-200301010-00004
(P698) 12514410